Johnson & Johnson to Settle Risperdal Improper Marketing Case

http://www.nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html?partner=rss&emc=rss

Federal officials said the drug giant promoted the antipsychotic drug as a way to treat dementia patients for many ailments, when it was only approved for schizophrenia.

Sent by gReader Pro

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s